The Japan Times - Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

EUR -
AED 4.212777
AFN 72.835586
ALL 94.512843
AMD 422.248264
ANG 2.053494
AOA 1052.895931
ARS 1680.790338
AUD 1.635257
AWG 2.067368
AZN 1.95436
BAM 1.956354
BBD 2.309354
BDT 140.73988
BGN 1.939347
BHD 0.432422
BIF 3423.630825
BMD 1.146945
BND 1.480319
BOB 7.92328
BRL 5.90941
BSD 1.146625
BTN 108.087801
BWP 15.582008
BYN 3.185903
BYR 22480.122
BZD 2.305963
CAD 1.623185
CDF 2615.035015
CHF 0.925648
CLF 0.026299
CLP 1035.072439
CNY 7.764364
CNH 7.780559
COP 3960.034063
CRC 520.14739
CUC 1.146945
CUP 30.394043
CVE 110.569964
CZK 24.190336
DJF 203.835517
DKK 7.474072
DOP 66.986043
DZD 152.939427
EGP 57.331754
ERN 17.204175
ETB 181.647461
FJD 2.564
FKP 0.866759
GBP 0.866531
GEL 3.039852
GGP 0.866759
GHS 12.874504
GIP 0.866759
GMD 84.304874
GNF 10064.442782
GTQ 8.746478
GYD 239.84901
HKD 8.988436
HNL 30.606273
HRK 7.533248
HTG 149.77244
HUF 351.906109
IDR 20445.785654
ILS 3.394682
IMP 0.866759
INR 108.1919
IQD 1502.49795
IRR 1577049.375404
ISK 143.976448
JEP 0.866759
JMD 181.171337
JOD 0.813229
JPY 185.008009
KES 148.419043
KGS 100.300781
KHR 4599.249852
KMF 492.617229
KPW 1032.250901
KRW 1752.130969
KWD 0.353179
KYD 0.955446
KZT 559.543917
LAK 25295.872375
LBP 102708.92515
LKR 382.668433
LRD 208.916469
LSL 18.815678
LTL 3.386631
LVL 0.693776
LYD 7.311819
MAD 10.580612
MDL 20.248208
MGA 4817.169398
MKD 61.628611
MMK 2407.987936
MNT 4106.547494
MOP 9.256923
MRU 45.947051
MUR 54.881752
MVR 17.720734
MWK 1992.243861
MXN 19.872546
MYR 4.745948
MZN 73.301688
NAD 18.814173
NGN 1560.350288
NIO 41.990088
NOK 11.102658
NPR 172.945006
NZD 1.997675
OMR 0.441554
PAB 1.14663
PEN 3.881306
PGK 5.032508
PHP 69.638491
PKR 319.223511
PLN 4.259467
PYG 7041.056554
QAR 4.175458
RON 5.239364
RSD 117.183799
RUB 83.845404
RWF 1679.12748
SAR 4.299026
SBD 9.24601
SCR 15.693948
SDG 688.744688
SEK 10.986379
SGD 1.482316
SHP 0.85631
SLE 28.387314
SLL 24050.86738
SOS 655.483268
SRD 42.898615
STD 23739.445827
STN 24.544623
SVC 10.032843
SYP 126.774237
SZL 18.814083
THB 37.723444
TJS 10.63456
TMT 4.014308
TND 3.339618
TOP 2.761569
TRY 53.26206
TTD 7.775237
TWD 36.375404
TZS 3017.595134
UAH 51.508996
UGX 4173.182519
USD 1.146945
UYU 45.84299
UZS 13769.075108
VES 695.774297
VND 30176.12295
VUV 135.491976
WST 3.156157
XAF 656.142926
XAG 0.017685
XAU 0.000276
XCD 3.099677
XCG 2.066386
XDR 0.807102
XOF 648.024305
XPF 119.331742
YER 273.665193
ZAR 18.876464
ZMK 10323.847966
ZMW 20.552914
ZWL 369.315822
  • CMSC

    0.0500

    22.37

    +0.22%

  • VOD

    -0.2300

    14.3

    -1.61%

  • CMSD

    0.0000

    22.29

    0%

  • NGG

    -1.2400

    79.44

    -1.56%

  • RELX

    -0.8300

    31.18

    -2.66%

  • RBGPF

    -0.5300

    60.61

    -0.87%

  • RYCEF

    -0.0300

    18.4

    -0.16%

  • BCE

    0.0000

    23.28

    0%

  • RIO

    -2.5900

    100.08

    -2.59%

  • BCC

    3.8500

    74.66

    +5.16%

  • JRI

    0.0500

    12.67

    +0.39%

  • GSK

    -1.4800

    50.67

    -2.92%

  • BTI

    -0.5800

    58.91

    -0.98%

  • BP

    -1.0400

    39.1

    -2.66%

  • AZN

    -2.9600

    174.93

    -1.69%

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives
Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

  • Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operations

  • Integrated platform accelerates pharmaceutical access, fulfillment, and commercialization

  • Combined ecosystem provides potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks

Text size:

TAMPA, FL / ACCESS Newswire / April 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced the execution of a definitive joint venture agreement with Kare PharmTech's wholly owned subsidiary, Kare Rx Hub, LLC ("KareRx"), an artificial intelligence (AI)-driven digital hub supporting retail pharmacy, telemedicine, and specialty pharmaceutical programs.

The execution of the joint venture formalizes the previously announced non-binding letter of intent and represents a significant milestone in aligning both organizations' technology platforms and operational teams into a unified ecosystem designed to accelerate patient access and improve the efficiency of pharmaceutical commercialization. By integrating the Wellgistics Hub technology stack including proprietary platforms EinsteinRx™ and HubRx AI™ with KareRx's digital hub, the combined platform is positioned to streamline the prescription journey from intake through fulfillment.

Prashant Patel, Chief Executive Officer of Wellgistics Health, commented, "This joint venture reflects our continued focus on building an integrated, technology-enabled platform to improve coordination across the prescription journey and support patient access to therapies. By combining KareRx's provider connectivity and digital engagement capabilities with our infrastructure, we believe this collaboration enhances operational efficiency and supports manufacturers and other healthcare stakeholders in navigating access pathways more effectively."

The joint venture aligns clinical, operational, and commercial teams across both organizations, enabling more seamless coordination between providers, pharmacies, and patients. Through this integration, the platform enhances key capabilities including eligibility and benefits verification, prior authorization workflows, prescription routing, and direct-to-patient fulfillment. The combined ecosystem includes a growing national footprint of independent pharmacies, provider networks, and telehealth channels, with the ability to reach more than 200,000 patient lives based on third-party internal estimates.

Mital Panera, Founder and Chief Executive Officer of KareRx, added, "KareRx was developed to connect providers, pharmacies, and patients through technology-driven solutions. This joint venture allows us to extend those capabilities by leveraging Wellgistics' technology stack, pharma expertise, and operational infrastructure. We believe the combined platform will support improved connectivity across stakeholders and facilitate access to therapies across participating networks."

The collaboration further strengthens direct-to-patient (DTP) and decentralized care models, providing pharmaceutical manufacturers with a comprehensive platform that integrates access, affordability, and fulfillment into a single solution. Leveraging AI-driven insights and a fully integrated operational backbone, the joint venture is designed to reduce barriers to therapy initiation, improve adherence, and deliver enhanced visibility into patient access and program performance.

The joint venture remains subject to customary implementation steps, and there can be no assurance regarding the timing or extent of operational integration or the realization of anticipated benefits. Additional details regarding the joint venture agreement will be provided in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

About Kare PharmTech, LLC

Kare Rx Hub is an artificial intelligence (AI)-based digital hub for retail pharmacies, telemedicine portal, and specialty pharmaceutical 'lite' branded products with over 500 physician-provider relationships, 200 independent pharmacy relationships that market unique specialty pharmaceutical 'lite' products. Kare Rx Hub is owned by Kare Pharmtech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Wellgistics Media & Investor Contact
Media: [email protected]
Investor Relations: [email protected]

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire

M.Sugiyama--JT